San Francisco · Pre-Seed–Late Stage · 1 people tracked
Investment thesis
BioRock Ventures focuses on seed-sized investments into private life science companies building best-in-class, FDA-regulated therapeutic drugs. The fund invests across all disease areas, all stages, and all therapeutic modalities, participating from angel and seed through Series A and up to pre-IPO or M&A exits.
Source: firm website, verified Aug 7, 2026.
Team · 1 people
from the firm's website
What they invest in
from 5 of 6 portfolio companiesBiotech ×5Healthtech ×4Deep Tech ×1
HQs:United States×4
Investments · 6 tracked
founders shown can be your intro path
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Margaret FitzPatrick(Director)Patricia Martin(Director)
Co-investorsAdjuvant CapitalFlucas VenturesMountain Group CapitalRA CapitalHatteras Venture Partners
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
PartnerMary Wheeler· solo GP
Co-investorsCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalRA Capital
PartnerMary Wheeler· solo GP
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)Sean Ainsworth(Chief Executive Officer)Robert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)Scott McIvor(Chief Development Officer)Richard Chin, M.D.(Director)
Co-investorsBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital NetworkNYBC Ventures+1 more
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
Co-investorsBioBritSamsara BioCapitalPolaris Partners
PTM Therapeutics is a biotech company developing therapeutic antibodies that target Post Translational Modifications (PTMs) to create more disease-specific targets.
Biotech
Co-investorsBioBrit
Exits · 2
IPOs and acquisitions across the tracked portfolioAN2 TherapeuticsNASDAQ: ANTXVaxcyteNASDAQ: PCVX
Portfolio news
latest coverage across their companiesAN2 Therapeutics · ng.investing.com · Aug 19, 2026
Immusoft · immusoft.com · Mar 30, 2026
Frequently asked questions
- How many investments has BioRock Ventures made?
- BioRock Ventures has 6 tracked investments.
- What stage does BioRock Ventures invest at?
- BioRock Ventures invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What sectors does BioRock Ventures focus on?
- BioRock Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is BioRock Ventures located?
- BioRock Ventures is headquartered in San Francisco, US.
- Who does BioRock Ventures co-invest with?
- BioRock Ventures most often shares deals with BioBrit, RA Capital, Breakout Ventures, among 16 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.